{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:40:25Z","timestamp":1791193225733,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T00:00:00Z","timestamp":1412812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00280-014-2599-1","type":"journal-article","created":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T09:25:30Z","timestamp":1412760330000},"page":"1307-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial"],"prefix":"10.1007","volume":"74","author":[{"given":"V.","family":"Gotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leoncini-Franscini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Baerlocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Duchosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-1035-3","volume":"10","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J et al (2004) Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous; leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10:68\u201375","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2599_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054\u20131061","journal-title":"Leukemia"},{"key":"2599_CR3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","volume":"98","author":"R Gurion","year":"2013","unstructured":"Gurion R, Gafter-Gvili A, Vidal L et al (2013) Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 98:95\u2013102","journal-title":"Haematologica"},{"issue":"6","key":"2599_CR4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1349-7006.2012.02253.x","volume":"103","author":"K Ohnishi","year":"2012","unstructured":"Ohnishi K, Nakaseko C, Takeuchi J et al (2012) Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103(6):1071\u20131078","journal-title":"Cancer Sci"},{"issue":"5","key":"2599_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32(5):415\u2013423","journal-title":"J Clin Oncol"},{"key":"2599_CR6","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Druker BJ, Branford S et al (2014) Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. doi: 10.1007\/s12185-014-1566-2","journal-title":"Int J Hematol"},{"issue":"20","key":"2599_CR7","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade De","year":"2008","unstructured":"De Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26(20):3358\u20133363","journal-title":"J Clin Oncol"},{"issue":"2","key":"2599_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26(2):214\u2013224","journal-title":"Leukemia"},{"issue":"6","key":"2599_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","volume":"25","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury S, Talpaz M (2011) Managing resistance in chronic myeloid leukemia. Blood Rev 25(6):279\u2013290","journal-title":"Blood Rev"},{"issue":"8","key":"2599_CR10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","volume":"86","author":"A Gafter-Gvili","year":"2011","unstructured":"Gafter-Gvili A, Leader A, Gurion R et al (2011) High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2014systematic review and meta-analysis. Am J Hematol 86(8):657\u2013662","journal-title":"Am J Hematol"},{"key":"2599_CR11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","volume":"37","author":"HJ Kl\u00fcmpen","year":"2011","unstructured":"Kl\u00fcmpen HJ, Samer CF, Mathijssen RHJ et al (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37:251\u2013260","journal-title":"Cancer Treat Rev"},{"key":"2599_CR12","unstructured":"Summary of Product Characteristics\u2014Glivec 400\u00a0mg film-coated tablets. http:\/\/www.glivec.com\/files\/Glivec-400mg-coated.pdf"},{"issue":"Suppl 7","key":"2599_CR13","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann J-L et al (2012) Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii72\u2013vii77","journal-title":"Ann Oncol"},{"key":"2599_CR14","unstructured":"NCCN Guidelines Version 2.2012 Chronic Myelogenous Leukemia. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"issue":"32","key":"2599_CR15","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","volume":"30","author":"B Gao","year":"2012","unstructured":"Gao B, Yeap S, Clements A et al (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30(32):4017\u20134025","journal-title":"J Clin Oncol"},{"key":"2599_CR16","first-page":"1537","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F et al (2009) Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leuk Off J Leuk Soc Am Leuk Res Fund 23:1537\u20131544","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund"},{"issue":"1","key":"2599_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","volume":"34","author":"JFT Teng","year":"2012","unstructured":"Teng JFT, Mabasa VH, Ensom MHH (2012) The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 34(1):85\u201397","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2599_CR18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","volume":"35","author":"V Gotta","year":"2013","unstructured":"Gotta V, Buclin T, Csajka C, Widmer N (2013) Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit 35(2):150\u2013167","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2599_CR19","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028","journal-title":"Blood"},{"issue":"8","key":"2599_CR20","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499","journal-title":"Blood"},{"issue":"9","key":"2599_CR21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F et al (2009) Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23(9):1537\u20131544","journal-title":"Leukemia"},{"issue":"1","key":"2599_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1470-2045(10)70258-8","volume":"12","author":"T Buclin","year":"2011","unstructured":"Buclin T, Widmer N, Biollaz J, Decosterd LA (2011) Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol. 12(1):9\u201311","journal-title":"Lancet Oncol."},{"issue":"12","key":"2599_CR23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","volume":"50","author":"C Bardin","year":"2014","unstructured":"Bardin C, Veal G, Paci A et al (2014) Therapeutic drug monitoring in cancer\u2014are we missing a trick? Eur J Cancer 50(12):2005\u20132009","journal-title":"Eur J Cancer"},{"issue":"12","key":"2599_CR24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","volume":"50","author":"N Widmer","year":"2014","unstructured":"Widmer N, Bardin C, Chatelut E et al (2014) Review of therapeutic drug monitoring of anticancer drugs part two\u2014targeted therapies. Eur J Cancer 50(12):2020\u20132036","journal-title":"Eur J Cancer"},{"key":"2599_CR25","first-page":"7","volume":"72","author":"V Gotta","year":"2011","unstructured":"Gotta V, Vallotton L, Widmer N, Buclin T (2011) Need of reduced and harmonized bureaucracy in multi-centre clinical research\u2014a case-report from a swiss trial. Br J Clin Pharmacol 72:7","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2599_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","volume":"51","author":"V Gotta","year":"2012","unstructured":"Gotta V, Widmer N, Montemurro M et al (2012) Therapeutic drug monitoring of imatinib bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 51(3):187\u2013201","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"2599_CR27","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","volume":"877","author":"A Haouala","year":"2009","unstructured":"Haouala A, Zanolari B, Rochat B et al (2009) Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci 877(22):1982\u20131996","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"issue":"4","key":"2599_CR28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","volume":"75","author":"A Haouala","year":"2013","unstructured":"Haouala A, Widmer N, Guidi M et al (2013) Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol 75(4):1007\u20131018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2599_CR29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","volume":"22","author":"NC Cross","year":"2009","unstructured":"Cross NC (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):355\u2013365","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2599_CR30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","volume":"37","author":"HJ Klumpen","year":"2011","unstructured":"Klumpen HJ, Samer CF, Mathijssen RH et al (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4):251\u2013260","journal-title":"Cancer Treat Rev"},{"key":"2599_CR31","unstructured":"Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01031628"},{"issue":"23","key":"2599_CR32","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"issue":"6","key":"2599_CR33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"7","key":"2599_CR34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N et al (2014) Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38(7):764\u2013772","journal-title":"Leuk Res"},{"issue":"1","key":"2599_CR35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","volume":"24","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Hochhaus A, Cortes J et al (2010) Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24(1):6\u201312","journal-title":"Leukemia"},{"issue":"3","key":"2599_CR36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","volume":"115","author":"HM Kantarjian","year":"2009","unstructured":"Kantarjian HM, Larson RA, Guilhot F et al (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3):551\u2013560","journal-title":"Cancer"},{"issue":"12","key":"2599_CR37","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12):5143\u20135150","journal-title":"Blood"},{"issue":"2","key":"2599_CR38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00280-012-2035-3","volume":"71","author":"P Gandia","year":"2013","unstructured":"Gandia P, Arellano C, Lafont T et al (2013) Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? Cancer Chemother Pharmacol 71(2):531\u2013536","journal-title":"Cancer Chemother Pharmacol"},{"key":"2599_CR39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","volume":"24","author":"SJ Seong","year":"2013","unstructured":"Seong SJ, Lim M, Sohn SK et al (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24:756\u2013760","journal-title":"Ann Oncol"},{"issue":"7","key":"2599_CR40","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","volume":"21","author":"RJ Li","year":"2010","unstructured":"Li RJ, Zhang GS, Chen YH et al (2010) Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 21(7):1506\u20131514","journal-title":"Ann Oncol"},{"issue":"4","key":"2599_CR41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P Coutre Le","year":"2004","unstructured":"Le Coutre P, Kreuzer K-A, Pursche S et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53(4):313\u2013323","journal-title":"Cancer Chemother Pharmacol"},{"key":"2599_CR42","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-12-2570","volume":"18","author":"I Judson","year":"2012","unstructured":"Judson I (2012) Therapeutic drug monitoring of imatinib-new data strengthen the case. Clin Cancer Res 18:5517\u20135519","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2599_CR43","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon F-X et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"1","key":"2599_CR44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-012-1998-4","volume":"71","author":"P-H Hsyu","year":"2013","unstructured":"Hsyu P-H, Mould DR, Upton RN, Amantea M (2013) Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol 71(1):209\u2013218","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2599-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2599-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2599-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T19:58:22Z","timestamp":1565899102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2599-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,9]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2599-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,9]]}}}